Infliximab-induced lichen planopilaris

Annals of Pharmacotherapy

Volumn 44, Issue 9, 2010, Pages 1501-1503

  Fernández Torres, Rosa ^a   Paradela, Sabela ^a   Valbuena, Luis ^a   Fonseca, Eduardo ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Anti tumor necrosis factor; Infliximab; Lichen planopilaris; Lichen planus; Lichenoid eruption

Indexed keywords

CYCLOSPORIN; DEFLAZACORT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN;

ADULT; ANEMIA; ARTICLE; CASE REPORT; CONNECTIVE TISSUE DISEASE; DRUG DOSE REDUCTION; EPIDERMIS; ERYTHEMA; ERYTHRODERMA; EYEBROW; FEVER; FOOT; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; KERATOSIS; LEG EDEMA; LICHEN; LICHEN PLANOPILARIS; LIVER FUNCTION TEST; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; PAPULE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PUSTULE; PUVA; RESPIRATORY TRACT INFECTION; SCALP; SIDE EFFECT; SKIN BIOPSY; TELANGIECTASIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALOPECIA; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG RESISTANCE; HUMANS; LICHEN PLANUS; MALE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956259302     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P079     Document Type: Article

References (16)

1. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009;61:486-504.
2. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Br J Dermatol 2007;156:486-91. (Pubitemid 46253946)
3. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies. Analysis of 233 cases. Medicine 2007;86:242-50.
4. Battistella M, Rivet J, Bachelez H, Liote F. Lichen planus associated with etanercept. Br J Dermatol 2008;158:188-9.
5. Vergara G, Silvestre JF. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002;138: 1258-9.
6. Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo RM, Delaporte E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann Dermatol Venereol 2007;134:337-42.
7. Bovenschen HJ, Kop EN, Van de Kerkhof PCM, Seyger MMB. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatol Treat 2006;17:381-3.
8. De Simone C, Caldarola G, D'Agostino M, Rotoli M, Capizzi R, Amerio P. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008;22:626-7.
9. Moss AC, Treister NS, Marsee DK, Cheifetz AS. Clinical challenges and images in GI: oral lichenoid reaction in a patient with Crohn's disease receiving infliximab. Gastroenterology 2007;132:488, 829.
10. Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-a antagonists. J Am Acad Dermatol 2009;61:104-11.
11. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003;206:388-90. (Pubitemid 36677038)
12. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
13. Erdem MT, Gulec AI, Kiziltunc A, Yildirim A, Atasoy M. Increased serum levels of tumor necrosis factor alpha in lichen planus. Clin Exp Dermatol 2003;207:367-70.
14. Fiorentino DF. The yin and yan of TNF-α inhibition. Arch Dermatol 2007;143:233-6.
15. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004;38:54-7. DOI 10.1345/aph.1C477
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)